Title: DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.

Authors: Gomih, Ayodele; Smith, Jennifer S; North, Kari E; Hudgens, Michael G; Brewster, Wendy R; Huang, Zhiqing; Skaar, David; Valea, Fidel; Bentley, Rex C; Vidal, Adriana C; Maguire, Rachel L; Jirtle, Randy L; Murphy, Susan K; Hoyo, Cathrine

Published In Int J Cancer, (2018 Aug 01)

Abstract: The role of host epigenetic mechanisms in the natural history of low-grade cervical intraepithelial neoplasia (CIN1) is not well characterized. We explored differential methylation of imprinted gene regulatory regions as predictors of the risk of CIN1 regression. A total of 164 patients with CIN1 were recruited from 10 Duke University clinics for the CIN Cohort Study. Participants had colposcopies at enrollment and up to five follow-up visits over 3 years. DNA was extracted from exfoliated cervical cells for methylation quantitation at CpG (cytosine-phosphate-guanine) sites and human papillomavirus (HPV) genotyping. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression to quantify the effect of methylation on CIN1 regression over two consecutive visits, compared to non-regression (persistent CIN1; progression to CIN2+; or CIN1 regression at a single time-point), adjusting for age, race, high-risk HPV (hrHPV), parity, oral contraceptive and smoking status. Median participant age was 26.6 years (range: 21.0-64.4 years), 39% were African-American, and 11% were current smokers. Most participants were hrHPV-positive at enrollment (80.5%). Over one-third of cases regressed (n = 53, 35.1%). Median time-to-regression was 12.6 months (range: 4.5-24.0 months). Probability of CIN1 regression was negatively correlated with methylation at IGF2AS CpG 5 (HR = 0.41; 95% CI = 0.23-0.77) and PEG10 DMR (HR = 0.80; 95% CI = 0.65-0.98). Altered methylation of imprinted IGF2AS and PEG10 DMRs may play a role in the natural history of CIN1. If confirmed in larger studies, further research on imprinted gene DMR methylation is warranted to determine its efficacy as a biomarker for cervical cancer screening.

PubMed ID: 29490428

MeSH Terms: Adult; Aged; Biopsy; CpG Islands; DNA Methylation*; Disease Progression; Epigenesis, Genetic; Female; Genomic Imprinting*; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Regulatory Sequences, Nucleic Acid*; Uterine Cervical Neoplasms/epidemiology; Uterine Cervical Neoplasms/etiology; Uterine Cervical Neoplasms/genetics*; Uterine Cervical Neoplasms/pathology*; Young Adult